Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 15/20 | 0.61 |
| ▸ | HEXA | P06865 | 2/20 | 0.52 |
| ▸ | HEXB | P07686 | 2/20 | 0.52 |
| ▸ | DHFR | P00374 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16275223 | 0.89 | REN (0.49) | GHSR | |
| SCHEMBL3635134 | 0.78 | GHSR (0.72) | GHSRDHFR | |
| SCHEMBL16275259 | 0.77 | REN (0.52) | GHSRHEXAHEXBTP53 | |
| SCHEMBL6246829 | 0.76 | GHSR (0.63) | GHSRHEXAHEXBDHFRMEN1 | |
| SCHEMBL6245988 | 0.74 | GHSR (0.89) | GHSRDHFR | |
| SCHEMBL6244563 | 0.74 | GHSR (0.71) | GHSRHEXAHEXBDHFRMEN1 | |
| SCHEMBL3631623 | 0.72 | GHSR (0.62) | GHSRDHFR | |
| SCHEMBL3638616 | 0.72 | GHSR (0.75) | GHSRDHFR | |
| SCHEMBL16275221 | 0.72 | HEXA (0.64) | GHSRHEXAHEXBDHFRMEN1 | |
| SCHEMBL6243638 | 0.71 | GHSR (0.90) | GHSRDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152560-A1 | Compounds for the treatment of hypertension and hypertensive end stage renal disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-06-02 | — | — | US | disclosed |
| US-20160152560-A1 | Compounds for the treatment of hypertension and hypertensive end stage renal disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-06-02 | — | — | US | disclosed |
| WO-2014193969-A2 | COMPOUNDS FOR THE TREATMENT OF HYPERTENSION AND HYPERTENSIVE END STAGE RENAL DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152560-A1 | Compounds for the treatment of hypertension and hypertensive end stage renal disease | REN, GLS, EDNRB | GHSR 587/4885HEXA 2706/4885HEXB 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.